ImageneBio

ImageneBio is a clinical-stage biotechnology company boldly imagining a world where patients can be free from the burden of severe immune/autoimmune and inflammatory ("I&I") diseases. Imagene aims to develop novel drugs with differentiated characteristics on a global scale, which can effectively control and alter the course of I&I diseases in affected patients, treat their symptoms, and improve quality of life. The company's lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that recently completed Phase 2a clinical trials for atopic dermatitis and alopecia areata. ImageneBio is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate to severe atopic dermatitis.